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Nearly half of the human genome is made of transposable elements (TEs) whose activity
continues to impact its structure and function. Among them, Long INterspersed Element class
1 (LINE-1 or L1) elements are the only autonomously active TEs in humans. L1s are expressed
and mobilized in different cancers, generating mutagenic insertions that could affect tumor
malignancy. Tumor suppressor microRNAs are ∼22nt RNAs that post-transcriptionally reg-
ulate oncogene expression and are frequently downregulated in cancer. Here we explore
whether they also influence L1 mobilization. We show that downregulation of let-7 correlates
with accumulation of L1 insertions in human lung cancer. Furthermore, we demonstrate that
let-7 binds to the L1 mRNA and impairs the translation of the second L1-encoded protein,
ORF2p, reducing its mobilization. Overall, our data reveals that let-7, one of the most relevant
microRNAs, maintains somatic genome integrity by restricting L1 retrotransposition.
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Transposable elements (TEs) account for nearly half of thehuman genome1. However, the only TE that remainsautonomously active nowadays is a non-Long Terminal
Repeat (non-LTR) retrotransposon known as Long INterspersed
Element class 1 (LINE-1 or L1), whose mobilization continues to
impact our genome2. LINE-1s comprise >20% of our DNA1 but
only about 80–100 of the ~500,000 L1 copies present in the
average human genome are full-length elements that retain the
ability to mobilize and are thus called Retrotransposition-
Competent L1s (RC-L1s)3. RC-L1s belong to the human-
specific L1Hs subfamily, are 6 kb long and encode two proteins
(L1-ORF1p and L1-ORF2p) that are indispensable for retro-
transposition4. However, ORF2p is expressed at a significantly
lower level than ORF1p5,6, and these differences are thought to be
controlled at the level of translation7. L1-ORF1p is a 40 kDa RNA
binding protein with nucleic acid chaperone activity8,9, whereas
L1-ORF2p is a 150 kDa protein with Endonuclease (EN) and
Reverse Transcriptase (RT) activities10,11. RC-L1s mobilize by a
“copy-and-paste” mechanism, involving reverse transcription of
an RNA intermediate and insertion of its cDNA copy at a new
site in the genome (reviewed in2). Briefly, retrotransposition starts
with the transcription of a full-length RC-L1 bicistronic mRNA,
which is exported to the cytoplasm and translated, giving rise to
L1-ORF1p and L1-ORF2p that bind preferentially to the same L1
mRNA to form a ribonucleoparticle (RNP)12. The RNP gains
access to the nucleus where retrotransposition occurs by a
mechanism known as Target Primed Reverse Transcription
(TPRT)13,14. During TPRT, the endonuclease activity of L1-
ORF2p nicks the genomic DNA, and its reverse transcriptase
activity uses the L1 mRNA as a template to generate a new copy
of the element in a different genomic location. L1 can target all
regions of the genome, but integration is locally dictated by the
presence of a consensus sequence 5′-A/TTTT-3′, which is
recognized by L1 endonuclease activity and allows annealing of
L1 mRNA poly(A) to the target DNA15,16. Other non-
autonomous retrotransposons such as Alu and SINE-R/VNTR/
Alu (SVA) may hijack the L1-encoded proteins and be mobilized
in trans17,18. Furthermore, L1-encoded proteins can sporadically
generate pseudogenes using cellular mRNAs as templates19.
TEs can affect genome stability in several ways, including the
accumulation of insertions and rearrangements2,20. Genomic
alterations caused by L1 activity have resulted in several human
disorders21. Among these alterations, new L1 insertions can dis-
rupt a gene unit, induce changes in splicing patterns, or interfere
with transcription (reviewed in refs. 2 and21). Remarkably, new
L1 insertions accumulate not only during early embryogenesis
and in the germline, being transmitted to the next generation, but
also in cancer cells, which are characterized by genome instabil-
ity22–33 (thoroughly reviewed recently in refs. 34,35). In fact, L1s
are highly expressed and mobilized in a wide range of human
epithelial cancers23,24, and high levels of L1 mobilization are
found in lung and colorectal cancers23,29. Interestingly, several
reports have shown that somatic L1 insertions can drive tumor-
igenesis and may even have initiated the tumor in normal
cells23,25,27,28,36. Transcriptional control through methylation of
the L1 promoter is one of the main defence mechanisms against
L1 activity37,38, and it has been demonstrated that hypomethy-
lation of specific RC-L1s is associated with retrotransposition in
early tumorigenesis27,29. However, additional post-transcriptional
mechanisms that silence and reactivate L1 in somatic normal and
tumor cells are not completely understood yet.
MicroRNAs (miRNAs) are small RNAs that are loaded into the
Argonaute (AGO) proteins to form the RNA-Induced Silencing
Complex (RISC) and post-transcriptionally repress gene
expression39,40. Hundreds of bona fide miRNAs exist in humans
and each of them is predicted to target many mRNAs41.
Therefore, miRNAs could be influencing essentially all human
developmental, physiological, and pathological processes39. In
particular, overall miRNA dysregulation has been described in
cancer42,43. Interestingly, it was previously shown that mouse
embryonic stem cells (mESCs) lacking mature miRNAs (DGCR8
or Dicer knockout) accumulate LINE-1 mRNA44–46. Whereas the
increase in LINE-1 mRNA levels in the absence of DGCR8 was
attributed to reduced noncanonical functions of the Micro-
processor, which cleaves stem-loops present in L1 elements45, it
remains possible that miRNAs regulate L1 expression levels.
Consistently, a previous study reported that miR-128 represses
engineered L1 retrotransposition in cultured cells47. Thus, we
hypothesized that some miRNAs could control L1 retro-
transposition and that their misexpression in tumors could con-
tribute to increased LINE-1 mobilization.
To test this possibility, we first analyze whole genome sequen-
cing data from a panel of human lung tumor/normal pairs and
miRNA expression data from the same tumor samples. Notably,
we find that samples containing tumor-specific L1 insertions
express reduced levels of several members of the tumor suppressor
miRNA let-7 family, suggesting that this miRNA could influence
retrotransposition in vivo. Indeed, we further demonstrate that let-
7 binds directly to the L1-mRNA impairing L1-ORF2p translation,
and reduces L1 retrotransposition in cultured tumor cells. Alto-
gether, our results uncover a role for let-7 in maintaining genome
integrity and provide mechanistic insight into how down-
regulation of let-7 miRNAs in tumors may unleash L1 activity,
causing genome instability and driving tumor genome evolution.
Results
miRNA levels correlate with L1 activity in lung cancer. To
identify potential miRNAs whose deregulation could produce a
change in L1 retrotransposition in epithelial tumors, we focused
on Non-Small Cell Lung Cancer samples (NSCLC) from The
Cancer Genome Atlas (TCGA), as endogenous L1s are known to
retrotranspose efficiently in this tumor type23,29,33. We selected
all the samples (45 patients) for which whole-genome sequencing
data from tumor and matched normal lung tissue, together with
tumor miRNA-seq data, were available. We computationally
identified tumor-specific somatic L1 retrotransposon insertions
from whole-genome sequencing data using the MELT (Mobile
Element Locator Tool) software48. Briefly, MELT detects Mobile
Element Insertions (MEIs) by searching for discordant reads pairs
and split reads that are enriched at genome positions containing
new, non-referenced insertions48. First, to rule out possible biases
produced by different coverage or quality of sample pairs, we
analyzed the polymorphic germline L1 insertions identified by
MELT both in tumor and normal tissue. We excluded four
samples where this common reference polymorphic calls number
was abruptly reduced under 10% after filtering. In the 41 selected
samples, the number of polymorphic L1 insertions found in
tumor/normal DNA pairs was similar and at least 63% of them
were common to both DNAs (Supplementary Table 1). After
exclusion of polymorphic L1s49, we detected 413 putative de novo
L1 insertions specific to cancer samples, which were absent in
matched normal DNA from the same patient (Supplementary
Table 1 and Supplementary Data 1). The low number of putative
de novo insertions found in normal tissue but not in tumor tissue
(3 in the 41 samples), expected to be zero, confirmed the speci-
ficity of the method. Consistent with previous studies, 409 of the
413 tumor-specific de novo L1 insertions identified here occurred
in intronic and intergenic regions (Supplementary Data 1), likely
representing passenger mutations34,35.
To evaluate a possible correlation between L1 retrotransposi-
tion in lung cancer and miRNA expression, tumor samples were
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divided into two groups based on the presence (≥1) or absence (0)
of tumor-specific L1 insertions (Fig. 1a). Using available miRNA-
seq data across these samples in TCGA, we analyzed the
expression of 26 miRNAs that have been previously associated
with the development and/or progression of lung cancer, such as
the let-7 family, the miR-34 family, or the miR-17-92 cluster50
(Fig. 1b). Interestingly, we found that several members of the
tumor suppressor let-7 family (let-7a, let-7e, and let-7f) were
significantly downregulated in the samples with ≥1 tumor-specific
L1 insertions upon multiple t testing adjusted with False
Discovery Rate (FDR) < 0.01 (Fig. 1b and Supplementary Table 2).
This correlation was also found for let-7a and let-7f using a
different statistical analysis (Rank-sum test, Supplementary
Table 3). Although all the members of the let-7 family have a
similar mature sequence, and could potentially bind to the same
RNA targets, their genomic location and timing of expression are
markedly different51. Interestingly, reduced expression of let-7a
and let-7f has been observed in lung cancer samples52,53.
Additionally, miR-34a, another tumor suppressor miRNA54,
was also significantly reduced in samples with tumor-specific
L1 insertions (Fig. 1b and Supplementary Table 2). As a control,
analysis was repeated after L1 insertion counts were randomly
reassigned to each sample. No significant correlation was found
in any case (one example is shown in Supplementary Fig. 1a and
Supplementary Table 4). Notably, the differential expression of
let-7a, let-7e, let-7f, and miR-34a was also significant in a more
restrictive analysis where all the miRNAs expressed in lung tumor
samples (89 miRNAs) were considered (Supplementary Table 5).
Thus, even though we cannot rule out a possible bias in the
analysis due to sample variability and the limited number of cases
available, these data suggest that let-7 and miR-34a might control
the accumulation of new L1 insertions in human lung cancer
samples. Next, we used SQuIRE (Software for Quantifying
Interspersed Repeat Elements)55 to quantify L1Hs expression in
RNA-seq data from these tumor samples, available in TCGA. As
expected, L1Hs RNA levels were significantly increased in
samples with tumor-specific L1 insertions (Supplementary
Fig. 1b). However, L1Hs expression negatively correlates with
miR-34a but not with let-7 expression (Supplementary Fig. 1b).
To further corroborate our results, we analyzed the correlation
between miRNA expression and the number of tumor-specific L1
insertions identified by Helman and collaborators in a group of
46 lung tumor samples using Transpo-seq framework23 (13 of
them were also included in the previous analysis using MELT).
Remarkably, the expression levels of let-7 family members (let-7a
and let-7e) and miR-34a were again significantly reduced in those
tumors containing tumor-specific L1 insertions when the 26
miRNAs related to lung cancer were analyzed (Supplementary
Fig. 1c and Supplementary Table 6) as well as when all the
miRNAs expressed in lung were included (Supplementary
Table 7). Notably, the same analysis with the number of
insertions randomly reassigned to each sample did not show
any significant correlation with miRNA expression (Supplemen-
tary Fig. 1d and Supplementary Table 8). Lastly, the same analysis
was performed using 36 breast cancer samples which contain a
notably smaller number of tumor-specific L1 insertions per
sample as determined by Transpo-Seq23. No significant correla-
tion was found for any of the 26 miRNAs related to lung cancer
(Supplementary Fig. 1e and Supplementary Table 9) suggesting
that the contribution of let-7 and mir-34a to L1 mobilization
could be specific to some tumor types.
Overall, these results suggest that a downregulation of let-7
and/or miR-34 expression can influence the accumulation of
tumor-specific L1 insertions in lung cancer.
Let-7 regulates human LINE-1 retrotransposition in vitro. To
investigate whether there is a causal relationship between the
variation in let-7 and miR-34 expression levels and the accu-
mulation of L1 insertions in tumors, we tested the effect of these
miRNAs on L1 mobilization using the sRNA/L1 retro-
transposition assay, recently developed in our lab56. This protocol
combines the previously described cell culture-based LINE-1
retrotransposition reporter assay (reviewed in2) with miRNA
mimics or inhibitors. Briefly, in this assay, cells are transfected
with a plasmid containing an RC-L1 tagged with a reporter cas-
sette (Fig. 2a). This cassette consists of a reporter gene (REP) in
antisense orientation relative to the L1, equipped with its own
promoter and polyadenylation signal, but interrupted by an
Lung tumour samples from TCGA 





Analysis of miRNA expression
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Fig. 1 Let-7 and miR-34a are downregulated in lung tumor samples with tumor-specific L1 insertions. a Schematic representation of the bioinformatic
analysis used to identify differentially expressed miRNAs in lung cancer samples with or without tumor-specific L1 insertions. b A graph plot representing
the expression levels of miRNAs previously associated with lung cancer50 in lung tumor samples without (dark gray, N= 14) and with (light gray, N= 27)
tumor-specific L1 insertions identified by MELT. Differentially expressed miRNAs are marked with * and were identified applying an unpaired two-tailed
t test adjusted by FDR < 0.01. To enable the representation of all miRNAs in one graph, expression in reads per million (rpm) was relative to the maximum
value of each miRNA in each case. Source data are provided as a Source Data file. Whiskers were calculated using the Tukey method. Individual black dots
represent outliers. Boxes extend from 25th to 75th percentiles, and lines in the middle of the boxes represent the median.
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intron located in the same transcriptional orientation as the L1.
Thus, a functional reporter can only be produced after a suc-
cessful round of retrotransposition (Fig. 2a). For this assay, we
used cultured HeLa cells which express high levels of let-7a and
almost undetectable levels of miR-34a as analyzed by RT-qPCR
(Supplementary Fig. 2a). We next analyzed L1 activity upon
overexpressing let-7a and miR-34a, using transfected synthetic
miRNA mimics and a neomycin-resistance based retro-
transposition assay (using plasmid JM101/L1.3, Fig. 2b and
“Methods”). As a control, we performed a clonability assay co-
transfecting the miRNA mimics with a plasmid encoding a
constitutively-expressed neomycin-resistance gene (pU6iNeo) to
rule out possible effects of miRNA overexpression on cell growth
(Fig. 2b). In agreement with the above observation in lung tumor
samples, we reproducibly detected a significant decrease in L1
retrotransposition upon overexpression of let-7a in HeLa cells
without affecting the clonability of the cells (Fig. 2b, top panel).
Furthermore, as expected, overexpression of different let-7 family
members also reduced L1 retrotransposition (e.g. let-7b in Sup-
plementary Fig. 2b). Strikingly, overexpression of miR-34 did not
affect L1 mobilization or cell clonability in this assay (Fig. 2b,
bottom panel). Similarly, let-7 overexpression inhibits L1 retro-
transposition in HEK293T cells, which express lower endogenous
levels of this miRNA as compared to HeLa cells (Supplementary
Fig. 2a). We used a dual-luciferase reporter vector containing a
different RC-L1, L1RP (pYX014, Supplementary Fig. 2c). This
plasmid uses Firefly luciferase as retrotransposition indicator and
encodes a Renilla luciferase in the backbone to normalize for
transfection efficiency (Supplementary Fig. 2c). Notably, we
observed a consistent decrease in L1 retrotransposition upon co-
transfection of the let-7 mimic in HEK293T cells (measured as
the relative luminescence ratio (L1-Fluc/Rluc)) (Supplementary
Fig. 2c). As expected, an inactive L1RP containing two missense
mutations in the ORF1-encoded protein did not show luciferase
activity (plasmid pYX15, Supplementary Fig. 2c). Considering
that miRNAs downregulate the expression of their targets, the
decrease of L1 mobilization upon let-7 overexpression suggests
that L1 mRNA could be a bona fide let-7 target. Conversely, miR-
34 overexpression in HEK293T cells, where the endogenous levels
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Fig. 2 Let-7 regulates engineered human LINE-1 retrotransposition. a Left panel: rationale of the retrotransposition assay in cultured cells. From left to
right: transcription start site in the 5′UTR (black arrow), the two L1 open reading frames ORF1 (brown rectangle) and ORF2 (blue rectangle), the antisense-
oriented reporter cassette (white rectangles, backward REP) interrupted by an intron, and the reporter gene promoter (inverted black arrow). Black
lollipops represent poly(A) signals. TSD: Target Site Duplications. SD: Splicing Donor. SA: Splicing Acceptor. Right panel: reporter cassettes used in this
study: neomycin (NEO or mneoI) and blasticidin (BLAST or mblastI) resistance, enhanced green fluorescent protein (EGFP or megfpI), and firefly luciferase
(FLUC or mflucI). b, c Structures of pJM101/L1.3 and pU6iNeo constructs are shown. b HeLa cells were co-transfected with one of the plasmids and let-7a/
miR-34a mimic and their control (scr). c HeLa cells were co-transfected with one of the plasmids and let-7 inhibitor and their control (c-). In (b-c), a
representative well of three replicate is shown. Quantification of each experiment is shown at the right as average of three replicates ± s.d. d Structures of
pYX017 and pYX015 are shown. CAG: Chicken Actin Globin promoter. The asterisk symbol in pYX015 indicates the two point-mutations in L1-ORF1p that
abolish retrotransposition. Lung cancer cell lines A549 and SK-MES-1 were co-transfected with pYX017 or pYX015 and let-7 inhibitor or its control (c-).
Luciferase activity was measured 96 h post-transfection, and Firefly luciferase signal was normalized to Renilla luciferase to correct for differences in
transfection efficiency or cell survival. In both cases, averages of three replicates ± s.d. are shown. RLU: Relative Luminescence Units. In (b-d), an unpaired
two-tailed t test was used to calculate p value, the statistically significant exact p values are shown. Source data are provided as a Source Data file.
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to an increase in L1 retrotransposition using the dual-luciferase
reporter vector pYX014 (Supplementary Fig. 2d). The different
effects observed for miR-34 overexpression in HeLa (Fig. 2b) and
HEK293T cells (Supplementary Fig. 2d) suggest a potential
indirect and cell-type specific effect of miR-34 on L1
mobilization.
To further investigate the role of let-7 on the control of L1
mobilization, we performed another panel of cell culture-based
retrotransposition assays using a hairpin inhibitor to decrease
intracellular let-7 levels. Although the inhibitor used was designed
against let-7a, it has been shown to cross-react with other
members of the family57. Consistent with our previous results, we
found that depletion of let-7 in HeLa cells led to a two-fold
increase in L1 retrotransposition without affecting the clonability
of the cells using the neomycin-resistance cassette described
above (Fig. 2c). A similar increase in L1 retrotransposition was
observed in HEK293T cells upon let-7 depletion using an EGFP-
based reporter cassette and a different human RC-L1, LRE3
(plasmid 99-UB-LRE3, Supplementary Fig. 2e). Furthermore, we
confirmed that let-7 knock-down increased L1 retrotransposition
in HEK293T using the luciferase reporter vectors pYX014 and
pYX017 (Supplementary Fig. 2f). While both contain the same
active human L1, L1RP, in pYX014 it is transcribed from the
native promoter in the 5´UTR whereas, in pYX017, it is highly
transcribed from a CAG promoter.
Lastly, since our bioinformatic analysis showed an inverse
correlation between let-7 expression and accumulation of L1
insertions in human lung tumor samples, we analyzed whether
let-7 could regulate L1 retrotransposition in lung cancer cells. To
do that, we performed the luciferase-based retrotransposition
assay in two lung cancer cell lines with markedly different
endogenous levels of let-7, A549, and SK-MES-1 (Supplementary
Fig. 2g). Interestingly, we observed that, in both cell lines,
depletion of let-7 increased L1 retrotransposition by 2.5 times on
average (Fig. 2d). Altogether, these data indicate that let-7
negatively regulates human L1 mobilization in a variety of cancer
cell lines.
Let-7 binds directly to the coding sequence of L1 mRNA. The
aforementioned regulation could occur either by a direct inter-
action between let-7-guided RISC and L1 mRNAs, or by an
indirect effect, since let-7 could be regulating any host factor
involved in the multiple steps of the retrotransposition cycle58 or
in L1 control59. Since a direct effect would be sequence-depen-
dent, we performed a neomycin-resistance based retro-
transposition assays in HeLa cells using non-human active LINEs,
that differ in sequence from the human L1 but use the same
target-primed reverse transcription mechanism for mobilization.
Briefly, we used mouse TGF21 (L1GF subfamily) and zebrafish
L2-1 and L2-2 (L2 clade). Structures of the different LINEs are
shown in the left panel of Fig. 3a, and constructs are described in
the Methods section. Interestingly, we observed that only human
L1 mobilization was significantly affected by either the inhibition
(Fig. 3a) or the overexpression (Supplementary Fig. 3a) of let-7.
These results suggested a direct, sequence-dependent interaction
between let-7 and human L1 mRNA.
It is well established that miRNAs mostly bind their target
mRNAs in their 3′UTRs39, although 5′UTR and coding sequence
(CDS) binding sites have been described and validated60–62. Thus,
to find out where the putative let-7 binding site was located in L1
mRNA, we performed the same retrotransposition assays but
using an engineered human RC-L1 (L1.3) lacking either the 5′or
the 3′UTR (Fig. 3b and Supplementary Fig. 3b). Notably, the
effect of let-7 depletion or overexpression in engineered L1
mobilization was not abolished or reduced by the absence of
either 5′ or 3′ UTR, suggesting that let-7 interacts with the CDS of
human L1 mRNA (Fig. 3b and Supplementary Fig. 3b).
It has previously been described that L1-ORF1p often
aggregates in cytoplasmic foci and colocalizes with L1 mRNA
and AGO2 protein, the main component of the RISC
complex63,64. We further analyzed whether let-7 guides the RISC
complex to L1 mRNAs by RNA-Immunoprecipitation (RIP). For
this, we used a human embryonic teratocarcinoma cell line (PA-
1), characterized by high levels of endogenous LINE-1 mRNA
and L1-ORF1p65 and very low levels of let-7 miRNAs
(Supplementary Fig. 2g). Briefly, we overexpressed FLAG-
tagged AGO2, pulled it down, purified the endogenous bound
RNAs, and analyzed them by RT-qPCR (Fig. 3c). We reasoned
that if let-7 can bind L1 mRNA, let-7 overexpression should lead
to an increase in the abundance of endogenous L1 mRNAs
associated to AGO2. Strikingly, we observed an enrichment in the
amount of L1 mRNA bound to AGO2 upon overexpression of
let-7 resembling the behavior of HMGA2 mRNA (Fig. 3d), a well-
known target of let-766. In contrast, none of the negative controls
used, GAPDH and actin mRNAs, were enriched in the
immunoprecipitation (Fig. 3d). Thus, these data suggest that
let-7 guides Argonaute proteins to L1 mRNA, and that this
interaction occurs within the L1 CDS.
A functional let-7 binding site is located in L1-ORF2. We next
set out to predict and validate putative let-7 binding sites within
the CDS of the L1 mRNA. We used two different software
available online: miRanda67 and RNA2268. The best predicted
binding site for let-7 family by each method was located in
positions 2650-2671 (bs1) and 4596-4616 (bs2), respectively, in
the consensus L1Hs sequence (top panel, Supplementary Fig. 4a).
In order to validate them, five tandem copies of each binding site
(bs) were cloned in the 3′UTR region of the Renilla luciferase
(Rluc) gene in the psiCHECK-2 vector, which also encodes a
Firefly luciferase (Fluc) gene to correct for transfection efficiency
(left panel, Fig. 4b). As controls, an unrelated sequence of the
same length and a sequence with perfect complementarity to let-7
were cloned (no bs and perfect bs, respectively). Those constructs
were co-transfected with let-7 mimic in HEK293T cells. The
reporter constructs containing the RNA22-predicted binding site
(bs2) and the positive control (perfect bs), but not the one with
the miRanda-predicted binding site (bs1) or the negative control
(no bs), showed a reduction of the relative luciferase ratio (RLuc/
FLuc) upon let-7 overexpression (bottom panel, Supplementary
Fig. 4a). A deeper analysis of the residues in this region inter-
acting with let-7 miRNA using RNAhybrids software69 suggests
that the functional “bs2” is located within the CDS of L1-ORF2
(position 4587-4610 in L1.3, a commonly used human RC-L1,
accession code # L19088.170), between the RT and Cysteine-rich
domains of this protein (Fig. 4a, left panel). Importantly, it is
predicted to form a duplex with let-7 miRNA consisting of seven
Watson–Crick pairings at positions 3–9 followed by an adenine at
the mRNA nucleotide corresponding to the first nucleotide
position of the miRNA, resembling a previously described func-
tional noncanonical binding site termed offset 7-mer (Fig. 4a)71.
Altogether, these results suggest that this refined binding site,
hereafter referred to as “bs2rh” is a bona fide let-7 binding site. To
further validate this binding site (“bs2rh”) we generated a mutant
sequence (“bs2rhmut”, see Fig. 4b, left panel). Mutations intro-
duced in “bs2rh” are predicted to severely impede the duplex
formation between L1 mRNA and let-7 (Supplementary Fig. 4b).
Accordingly, the mutated sequence rescued the luciferase activity
upon overexpression of let-7 (bs2rh vs bs2rhmut, Fig. 4b).
To further corroborate the functionality of “bs2rh” in the
context of retrotransposition, we generated an allele mutated
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RC-L1 construct containing a mutated “bs2rh” site (we
introduced the same mutation described above, construct
JM101/bs2rhmut L1.3, Fig. 4c). Intriguingly, the validated “bs2rh”
site is conserved through primate L1 evolution, being present in
L1PA5 elements and containing a few mutations in older
L1 subfamilies (Supplementary Fig. 4c). Accordingly, the
introduction of the mutation contained in the “bs2rhmut”
sequence, which entails an amino acid change (P to G) in L1-
ORF2p, leads to a reduction in RC-L1 mobility (Fig. 4d, right side
graph). We observed that “bs2rhmut” L1.3 retrotransposition was
less affected by let-7 inhibition than wild-type L1.3 (Fig. 4d).
Interestingly, this binding site is absent in zebrafish LINEs and
relatively low conserved in mouse RC-L1s (Supplementary
Fig. 4d) in agreement with the specific let-7 effect on human L1
retrotransposition showed above (Fig. 3a and Supplementary
Fig. 3a). However, the fact that mutating this binding site reduced
but not abolished the effect of let-7 in L1 mobilization suggests
that additional mechanisms mediated by let-7 may work to
restrict human L1 retrotransposition. Overall, these results
suggest that there is at least a functional let-7 binding site in
the ORF2 region of human L1 mRNA.
Let-7 impairs L1-ORF2p translation. The above experiments
identified a functional let-7 binding site in L1-ORF2p, and we
next analyzed the functional consequences of let-7 binding to L1
mRNA. Since miRNAs can induce mRNA degradation40, we
analyzed the levels of endogenous L1 mRNAs upon let-7 over-
expression in HEK293T cells by RT-qPCR. We found no changes
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Fig. 3 Let-7 binds directly to the coding sequence of L1 mRNA. a Cell culture-based retrotransposition assay using mneoI reporter cassette. HeLa cells
were co-transfected with LINEs from different species and let-7 inhibitor or its control (c-). All constructs have an exogenous CMV promoter to normalized
transcription. Black arrows represent transcription start sites. Gray triangles in mouse and zebrafish LINEs illustrate the presence of monomers in the 5′
UTR of these elements. Stem loop (gray) pictures the hairpin structures present in the 3′ UTR of the zebrafish LINE-2s, required for retrotransposition.
White stripes are included to remark the differences in sequence of zebrafish L2-2 and L2-1 with respect to the human L1.3 and mouse L1GF. A
representative well is shown in the middle panel. Quantification is shown on the right as average ± s.d of three biological replicates. b Cell culture-based
retrotransposition assay with blasticidicin resistance cassette. HeLa cells were co-transfected with LINEs lacking either the 5′ or the 3′ UTR (structures
shown in the left) and let-7 inhibitor or its control (c-). A representative well of three replicates is shown. Quantification is shown at the right as average of
three replicates ± s.d. In (a–b), an unpaired two-tailed t test was used to calculate p value, and statistically significant exact p values are shown. Source data
are provided as a Source Data file. c Scheme of RNA Immunoprecipitation (RIP) of AGO2-FLAG and RT-qPCR analysis of endogenous mRNA enrichment
upon let-7 overexpression. Embryonic teratocarcinoma cells (PA-1) were co-transfected with a plasmid to overexpress AGO2-FLAG and let-7 mimic.
AGO2-FLAG (orange circle with green flag) was immunoprecipitated with a FLAG antibody (black circle and lines), and the RNA bound to AGO2 (L1
mRNA is shown in blue) was purified and analyzed by RT-qPCR. Transfection with pBSKS (empty vector) was used as a negative control. d Real-time RT-
qPCR analysis of endogenous L1 mRNA upon immunoprecipitation of AGO-2-FLAG of one representative experiment of three replicates. Left panel: loading
controls are shown for input and IP. Right panel: mRNA relative enrichment upon let-7 overexpression: LINE-1 (blue), HMGA2 (yellow), GAPDH (red), and
ACTIN (gray) are shown.
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whereas those of other canonical let-7 targets (DICER and
HMGA2) were reduced (Fig. 5a). Similarly, L1 mRNA levels were
not decreased upon let-7 overexpression (Supplementary Fig. 5a)
or increased upon let-7 depletion (Supplementary Fig. 5b) when
L1 was overexpressed in HEK293T cells. Thus, these data suggest
that let-7 expression does not trigger L1 mRNA degradation.
The other main effect of miRNAs on their target mRNAs is
interference with protein translation72, so we analyzed the levels
of endogenous L1-ORF1p upon modulation of let-7 levels in
HEK293T cells. We found significant changes in HMGA2 but not
in ORF1p expression upon let-7 overexpression (Fig. 5b) or
depletion (Supplementary Fig. 5c). We corroborated this results
in a stable HEK293T cell line that constitutively overexpresses a
T7-tagged L1-ORF1p (from L1.3, and using a CMV promoter)
(Supplementary Fig. 5d).
We next analyzed changes in L1-ORF2p levels. The translation
of ORF2p occurs by a highly inefficient unconventional
termination/reinitiation mechanism that, although could produce
as few as one L1-ORF2p molecule per L1 mRNA7, is enough to
support efficient retrotransposition4,7. Consequently, it is techni-
cally challenging to detect endogenous L1-ORF2p. Thus, to study
L1-ORF2p levels upon let-7 modulation, we generated a
monocistronic construct expressing 3xFLAG-tagged ORF2p from
a CMV promoter (L1-ORF2p from L1.3), pSA500. Strikingly, we
observed an increase in ORF2p upon let-7 depletion and a
decrease upon let-7 overexpression in HeLa cells (Fig. 5c)
resembling the effect on DICER protein levels, a well-described
target of let-7 with several 8-mer sites60 (Fig. 5c). To rule out that
differences in L1-ORF2p expression were due to different
transfection efficiencies, we took a fraction of each sample,
extracted DNA, and quantified plasmid levels by qPCR using
primers targeting the CMV promoter driving ORF2 expression or
the EBNA-1 sequence in the plasmid backbone. We did not
observe any significant differences in the amount of plasmid co-
transfected with let-7 mimic (Supplementary Fig. 5e) or let-7
inhibitor (Supplementary Fig. 5f). Consistent with the data
presented above, the difference at protein level neither correlates
with changes in the levels of exogenous L1 ORF2-FLAG RNA
(ORF2-F), as opposed to DICER whose mRNA is also reduced
(bottom panel, Fig. 5c). These data suggest that the differences in
ORF2p levels are not due to variations in transfection or mRNA
accumulation but to an effect of let-7 on ORF2-F translation.
To understand whether let-7 mediated translational repression
of ORF2p is due to the specific interactions with the offset 7-mer
site or to its location within the CDS, we generated three variants
of pSA500 in which we introduced different sequences in its 3′
UTR: a scrambled sequence (“scrb”), the binding site (“bs2rh”)
and a modified bs2 that contains a canonical 8-mer site for let-7
(“8mer”) (Supplementary Fig. 5g). We co-transfected all these
constructs in HeLa cells with let-7 mimic. First, by RT-qPCR
we observed that similar levels of transfection (measuring
constitutive EBNA expression from the plasmid backbone,
Supplementary Fig. 5h) and let-7 overexpression (measuring the
effect on endogenous DICER, Supplementary Fig. 5h) were
achieved. The levels of ORF2 mRNA were not significantly
affected in any case, although we observed a tendency towards a
reduction on the RNA levels upon placement of the binding
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Fig. 4 L1 mRNA contains a functional let-7 binding site located in L1-ORF2. a RNAhybrid prediction of the best binding site for let-7 located in the region
of L1Hs identified as “bs2” with RNA22. Base-pairing between this region and let-7b is shown (green rectangle). Localization of the putative binding site
(“bs2rh”) within L1 sequence is shown (green line). Structure of LINE-1 is shown: transcription start site (black arrow), 5′ untranslated region (UTR), ORF1,
ORF2 with its three domains endonuclease (EN), reverse transcriptase (RT), and cysteine-rich (C), and 3′ UTR. Folding energy of the predicted binding site
is shown below. b psiCHECK2 assay with “bsrh” and “bs2rhmut”. Left panel: scheme of psiCHECK2 plasmid containing SV40 promoter, Renilla luciferase
gene (RLuc, orange rectangle), different sequences cloned in the 3′UTR of the RLuc gene (gray rectangle), and Firefly luciferase gene (FLuc, brown
rectangle). Comparison of the sequences cloned in psiCHECK2 as “bs2rh” and “bs2rhmut” is shown below, with the nucleotides interacting with let-7 in
capital letters and the different nucleotides highlighted in red. Right panel: HEK293T cells were co-transfected with the different psiCHECK2 constructs and
scr or let-7 mimic. Data are presented as mean values ± s.d. of three replicates. Source data are provided as a Source Data file. RLU: Relative Luminescence
Units. Statistically significant exact p values are shown after applying an unpaired two-tailed t test. c Scheme of the wild type L1.3 and the binding site
mutant “bs2rhmut L1.3” generated by site-directed mutagenesis. Red thunder indicates location of the mutated binding site. d HeLa cells were co-
transfected with JM101/L1.3 or JM101/bs2rhmut L1.3 and let-7 inhibitor or its control (c-). A representative well of three replicates is shown. Quantification
is shown as retrotransposition rate (relative to c-) and raw colony count, in both cases as average of three replicates ± s.d. Source data are provided as a
Source Data file. Statistically significant exact p values are shown after applying an unpaired two-tailed t test.
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3′UTR (Supplementary Fig. 5h). Furthermore, western blot
analysis showed that placement of “bs2rh” sequence in the 3′
UTR of pSA500 slightly enhanced the reduction of ORF2-F
protein upon let-7 overexpression (Supplementary Fig. 5i), an
effect that was more prominent when the canonical site (“8mer”)
was tested. In agreement with previous studies71, these results
suggest that the proficiency of “bs2rh”, a noncanonical offset
7mer site, is weaker than that of a canonical let-7 binding site
when they are located in 3′UTR. Moreover, we cannot rule out
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Fig. 5 Let-7 impairs L1-ORF2p translation. a RT-qPCR analysis of endogenous LINE-1 (blue bar), HMGA2 (purple bar), DICER (green bar), and ACTIN
(orange bar) mRNAs upon let-7 overexpression in HEK293T. Cells were transfected with let-7 mimic or its control (scr), and RNA was extracted at 24 h or
48 h post-transfection. GAPDH was used to normalize. Data are presented as average ± s.d. of five biological replicates. b Western-blot analyses of
endogenous L1-ORF1p and HMGA2 protein levels in HEK293T cells upon let-7 overexpression. Cells were transfected with let-7 mimic. Representative well
and quantification of the western blot are shown. Data are presented as average ± s.d. of four replicates. c Western-blot analyses of L1-ORF2p-FLAG upon
let-7 overexpression or depletion in HeLa cells. A scheme of construct pSA500 is shown. HeLa cells were co-transfected with pSA500 and let-7 mimic or
inhibitor and their controls (scr or c- respectively). L1-ORF2p was detected using a FLAG antibody. DICER, a known let-7 target, was used as a positive
control. Representative well and quantification of the western blot are shown. Below, RT-qPCR analyses of the levels of DICER and L1-ORF2-3xFLAG mRNA
(ORF2-F) upon overexpression or depletion of let-7. GAPDH was used to normalize. Data are presented as average ± s.d of three replicates. d Flow
cytometry quantification of L1-ORF2p-mCherry levels upon let-7 depletion in HeLa cells. The structure of construct pVan583 is shown. pVan583 is a
derivative of JM101/L1.3 with L1-ORF1p fused to EGFP and L1-ORF2p fused to mCherry both at the C-terminus. HeLa cells were co-transfected with
pVan583 and let-7 inhibitor or its control (c-), and fluorescence was measured by flow cytometry. Graph shows the percentage of mCherry+ cells in the
EGFP+ (transfected) population. Data are presented as average ± s.d. of three replicates. A representative FACS histogram of three replicates in each
condition is shown (the percentage of ORF1p-GFP positive cells expressing ORF2p-Cherry protein). In (a–d), an unpaired two-tailed t test was used to
calculate p value, statistically significant exact p values are shown. Source data are provided as a Source Data file.
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located in 3′UTR could be attributed to mRNA destabilization.
Additionally, using site-directed mutagenesis we introduced two
point-mutations in the ORF2 coding region to transform the
offset 7-mer into a canonical let-7 8-mer site, generating pSA500-
ORF2-8mer (Supplementary Fig. 5j). We co-transfected this
construct in HeLa cells with let-7 mimic. Interestingly, the 8-mer
site within the ORF does not affect the levels of mRNA
(Supplementary Fig. 5k) and leads to a decrease in the protein
level similar to that observed above for “bs2rh” (Supplementary
Fig. 5l). Altogether, these results suggest that the translational
repression mediated by “bs2rh” mainly depends on its location
within the CDS, rather than on its noncanonical interaction.
To further characterize this effect, we next analyzed the impact
of let-7 binding on L1-ORF2p translation in its natural context: a
full-length bicistronic L1 RNA where L1-ORF2p is translated
using the aforementioned termination/reinitiation mechanism7.
In order to perform a more quantitative analysis, we combined
the use of L1-encoded proteins with fluorescent tags and confocal
microscopy or flow cytometry. Briefly, we generated a construct
where L1-ORF1p and L1-ORF2p from a human L1.3 element
were fused to EGFP and mCherry, respectively, at their C-
terminus (plasmid pVan583, Fig. 5d). First, we confirmed that
ORF1p-GFP was expressed from this construct (Supplementary
Fig. 5m) and that this tagged L1 was able to retrotranspose,
although the addition of both florescent tags reduced its activity
to ~30% of its untagged counterpart, JM101/L1.3 (Supplementary
Fig. 5n). Next, by confocal microscopy we observed a reduction of
L1-ORF2p-mCherry but not of L1-ORF1p-EGFP levels upon
overexpression of let-7 in U2OS cells (Supplementary Fig. 5p).
However, due to reduced transfection capacity of this construct
(Supplementary Fig. 5o) and the inefficient translation of ORF2p-
mCherry7, we obtained an insufficient number of double positive
cells to enable a quantitative analysis by microscopy. Therefore,
we turned to a more sensitive and quantitative approach: flow
cytometry. We co-transfected pVan583 with let-7 inhibitor in
HeLa cells and analyzed EGFP+ cells (i.e. >3500 cells per sample).
Notably, we found that depleting let-7 led to an increase in the
number of mCherry+ cells in the EGFP+ population suggesting
an increase in the synthesis of L1-ORF2p-mCherry (Fig. 5d).
Altogether, our results suggest that let-7 impairs L1-ORF2p
translation, potentially altering the ratio between L1-ORF1p and
L1-ORF2p, which we speculate could unbalance L1-RNP
formation (Fig. 6).
Discussion
Many studies have linked LINE-1 retrotransposons to can-
cer22–29,31–33. In particular, L1 insertions have been found to
occur at high frequencies in lung cancer genomes33. L1 is also
associated with genomic instability, since new insertions can
potentially cause splicing alterations, exon disruptions, indel
mutations, or large genomic rearrangements2,20,36. How these
elements are silenced and derepressed in somatic human tis-
sues, and how these processes impact tumorigenesis is an open
question. DNA methylation of the L1 promoter is an important
inhibitor of L1 activity37. In fact, a consistent correlation
between the number of somatic L1 insertions in lung cancer
and hypomethylation of L1 promoters has been shown, both at
a global and at a locus specific level29,38. However, considering
the high level of somatic L1 activity in some of these patients, it
is tempting to speculate that RC-L1s might also escape post-
transcriptional restriction mechanisms44,73. On the other hand,
among all tumor suppressor miRNAs, reduced let-7 expression
occurs most frequently in cancer and typically correlates with
poor prognosis74. Functionally, it is well known that a decrease
in let-7 miRNAs leads to overexpression of their oncogenic
targets such as MYC, RAS, HMGA2 among others51.
Here we describe a role for let-7 in controlling human L1 activity,
which may contribute to its tumor suppressor function. First, we
found a high frequency of retrotransposition in NSCLC cancer,
consistent with previous reports23,33. We further showed that
human tumor samples with somatic L1 insertions present reduced
let-7 expression. Additionally, we demonstrated that the mobiliza-
tion of full-length L1s in cultured cells can be negatively regulated
by let-7 in a variety of cell lines including lung cancer cells.
It is worth noting that the expression of another tumor sup-
pressor miRNA, miR-34a, is also reduced in lung tumors with L1
activity and correlates negatively with L1Hs RNA levels. How-
ever, we did not observe a consistent effect of the latter on L1
retrotransposition, under our experimental conditions. We
speculate that mir-34 could indirectly regulate L1 mobilization,
targeting a member of the epigenetic regulatory network con-
trolling the expression of active L1s in our genome.
AGO proteins are the main effectors of miRNA-guided gene
silencing75. Our AGO2 RNA-immunoprecipitation assay and the
use of engineered retrotransposition constructs lacking 3′UTR or
5′UTR suggest that let-7 is actually guiding AGO2 to the human
L1 mRNA, and that its binding occurs in L1 CDS. In fact, we have
demonstrated that ORF2 contains a noncanonical offset 7-mer
let-7 binding site previously described as functional for miRNA
targeting71. Although it is widely accepted that most binding sites
are located in the 3′UTR of target mRNAs39, functional CDS






























Fig. 6 Model for the control of LINE-1 retrotransposition by the tumor
suppressor miRNA let-7. Besides the well-known regulation of oncogenes
(lower part of the scheme in gray), we propose a novel tumor-suppressor
role for let-7 miRNAs (upper part of the scheme in color). Once LINE-1 RNA
is transcribed from an active L1 located in the genome and is exported into
the cytoplasm, let-7 (drawn in red) binds and guides the RISC complex
(gray circle) to the L1 mRNA (blue line). This binding leads to the inhibition
of ORF2p translation (blue circle) and consequently, impairs the formation
of the ribonucleoparticle (ORF1p (brown circle) and ORF2p (blue circle)).
The reduction in ORF2p levels results in a decrease in the reverse
transcriptase activity in the nucleus and the number of new L1 copies
integrated in the genome, consequently, reduces the L1-associated genomic
instability.
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Furthermore, we demonstrate that mutations in this binding
site reduce, but not abolish, the effect of let-7 modulation on
human L1 mobility. These results suggest that additional let-7
binding sites may exist within the CDS of human L1 mRNA, or
that let-7 might have redundant indirect effects. However, we
failed to validate functional let-7 binding sites in a different L1-
ORF2 region (“bs1”, identified by miRanda, Supplementary
Fig 4a). Thus, alternative approaches might be needed to obtain
an unbiased view of functional let-7 binding sites in the L1
mRNA. Importantly, the binding site for the only miRNA tar-
geting human LINE-1 mRNA described so far, miR-128, is also
located in L1-ORF247. We speculate that L1-ORF2, the largest
and most conserved region among human LINE-1 subfamilies, is
preferentially targeted by miRNAs because of the restricted space
in the short L1 3′UTR, as it has been suggested by computational
analysis for other mRNAs76. Accordingly, it was previously
shown that knocking down the Microprocessor complex
increased retrotransposition of a LINE-1 lacking the 3′UTR to the
same extent as that of a full-length element45. Moreover, con-
sistent with the mechanism suggested for gene silencing mediated
by miRNA binding sites located in CDS61,77, we have demon-
strated that let-7 impairs translation of L1 ORF2p without
affecting mRNA stability. This conclusion is further supported by
the fact that no correlation between the levels of let-7 and the
expression of L1Hs RNA was observed in human lung tumor
samples (Supplementary Fig. 1b). Interestingly, the accumulation
and translation of an L1 mRNA variant that has the natural
“bs2rh” site substituted by a canonical let-7 8-mer site is similarly
affected by let-7 overexpression as wild-type molecules (Supple-
mentary Fig. 5j–m). This suggests that binding to the CDS region
itself rather than the structure of base-pairing mediates transla-
tional repression, as previously described for other miRNA tar-
geting CDS sites61.
Since L1-ORF2p is expressed at a very low level and is essential
for L1 retrotransposition4, a small reduction in the abundance of
this protein could unbalance RNP formation reducing human L1
mobilization. Besides binding L1-ORF2 sequences, let-7 could
also be regulating other mRNAs encoding proteins that positively
impact human L1 retrotransposition59.
Notably, even though the let-7 miRNA-L1 mRNA interaction
likely occurs in any cell that simultaneously expresses both RNAs,
we did not observe any correlation between increased somatic L1
insertions and reduced let-7 levels in human breast cancer sam-
ples (Supplementary Fig. 1e). We speculate that in some cell
types, other regulatory layers that suppress L1 mobilization at
transcriptional or post-transcriptional levels73 may overshadow
miRNA-mediated L1 inhibition. Consistently, L1 reactivation is
less frequent in breast cancer than in other type of tumors such a
NSCLC23,29,36, suggesting that in breast cancer additional
mechanisms of control could be restricting L1 retrotransposition
despite a reduced expression of let-7.
Let-7 is one of the most highly conserved families of miRNAs
in the animal kingdom and is involved in multiple biological
processes including differentiation, cell death, metabolism, and
cancer51. Here, all our findings support a model in which
let-7 also guides the RISC to the mRNA of active L1s and impairs
L1-ORF2p translation, altering the ratio between L1-ORF2p and
L1-ORF1p in the L1-RNP and consequently reducing LINE-1
retrotransposition (Fig. 6). Mature let-7 is highly expressed in
differentiated cells51, where different mechanisms repress L1
activity to avoid somatic L1 insertions38,73. We hypothesize that
alterations in let-7 expression in human cancer lead to an
increased mobilization of actively transcribed L1s and, moreover
L1- mediated retrotransposition of non-autonomous transposable
elements like Alu and SVA35, increasing genome instability and
contributing to tumor progression.
Methods
Sequencing data. Both WGS (aligned to HG19), miRNA expression quantification
and RNA-seq raw sequencing data files from TCGA were obtained from the
Genomic Data Commons (GDC) Legacy Archive using the GDC Data Transfer
Tool78. Cases of paired tumor-normal whole-genome sequencing (WGS) where
tumor miRNAs expression data was available were retrieved for lung adenocarci-
noma (LUAD) and lung squamous cell carcinoma (LUSC). High coverage (28-95x)
WGS files aligned to hg19 from primary tumor and solid tissue normal samples,
and miRNA gene quantification files from primary tumor were downloaded for
LUAD (17 patients) and LUSC (28 patients).
WGS analysis. Putative somatic LINE-1 insertion calls for both normal tissue
(NT) and primary tumor (PT) were obtained using MELT version 2.1.548. To
discard possible sequencing artifacts, candidate somatic insertions were further
filtered including calls supported with a minimum of three split-reads, with the
highest accuracy assessment for breakpoint detection and passing all internal filters
(MELT parameters ASSESS= 5 and FILTER= PASS). Polymorphic insertion calls
were found using a curated database included in TEBreak software (https://github.
com/adamewing/tebreak) and excluded from final results.
Several quality values were checked as a measure of filtering effects on original
(unfiltered) MELT results. First, somatic insertions found in NT alone, and NT and
PT simultaneously were expected to be zero, and only a maximum of one insertion
was allowed for these values. All samples passed this additional filtering.
Furthermore, polymorphic L1 insertions after MELT filtering were controlled,
requiring that a similar number was found for PT and NT samples, and that this
number were uncorrelated with sample coverage. Four samples in LUSC (TCGA-
60-2695, TCGA-60-2722) and LUAD (TCGA-55-1594, TCGA-55-1596) were
excluded from analysis because only a low number (<10%) of polymorphic
insertions passed all filters.
Filtered LINE-1 calls were considered tumor somatic insertions if detected in
primary tumor filtered results and absent in unfiltered solid normal tissue insertion
set within a range of 100 bp.
Correlation with miRNA expression. Samples were divided into two groups
depending on whether putative somatic insertions were or were not found in the
primary tumor. Only miRNAs with medium-high expression (over 100 reads per
million (RPM) mapped reads) were considered. For some of the analysis, expres-
sion of specific miRNAs known to be involved in the development and progression
of lung cancer was analyzed.
For each miRNA, outliers were discarded (we considered outliers values
deviating more than two standard deviations from the mean in each group).
Differentially expressed miRNAs were identified applying an unpaired two-tailed t
test adjusted by FDR= 1%. Results were confirmed using a rank-sum test. RPMs
were normalized to the highest expression value of each miRNA to enable
visualization of all miRNAs in the same graph. Tumor-suppressor miRNAs and
oncomiRs related to lung cancer used for this analysis were described in a recent
revision50. As a control, L1 insertion numbers were randomly reassigned to each
sample and analysis was repeated. Moreover, analysis was done with L1 insertions
determined by Helman and col. using Transpo-seq in lung and breast cancer
samples obtained from TGCA as well23. Data processing and analysis were
performed as described above.
L1Hs RNA expression. To analyze global TE expression in RNA-seq experiments,
we use SQuIRE55 (Software for Quantifying Interspersed Repeat Elements).
SQuIRE quantifies expression at the subfamily level. It outputs read counts and
fragments per kilobase transcript per million reads FPKM. Linear correlation
between L1Hs RNA levels and miRNAs expression was calculated using Pearson
Correlation Coefficient in GraphPad Prism 6.
Cell culture. HEK293T, PA-1, HeLa, and U2OS cells were originally obtained from
ATCC and were provided by Drs Jose Luis Garcia-Perez (IGMM, Edinburgh, UK)
and John V. Moran (University of Michigan, US). Lung cancer cell lines (A549, SK-
MES-1) were provided by Dr Pedro Medina (GENYO, Spain). Stable Flp-In-293
cells expressing T7-tagged L1-ORF1p were previously generated for a different
study79.
HEK293T, HeLa, U2OS, A549, and SK-MES1 cells were cultured in high-
glucose Dulbecco’s Modified Eagle’s Media (DMEM, Gibco) supplemented with
GlutaMAX, 10% fetal bovine serum (FBS, Hyclone) and 100 U/mL
penicilin–streptomycin (Invitrogen).
PA-1 cells were cultured in Minimal Essential Medium (MEM, Gibco)
supplemented with GlutaMAX, 10% heat-inactivated FBS (Gibco), 100 U/mL
penicilin-streptomycin (Invitrogen) and 0.1 mM Non-Essential Amino Acids
(Gibco).
All cells were maintained in humidified incubators at 37 °C with 5% CO2. The
absence of Mycoplasma spp. in cultured cells was confirmed at least once a month
by a PCR-based assay (Minerva). Cell identity was confirmed at least once a year
using the STR genotype (at Lorgen, Granada).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19430-4
10 NATURE COMMUNICATIONS |         (2020) 11:5712 | https://doi.org/10.1038/s41467-020-19430-4 | www.nature.com/naturecommunications
Retrotransposition assays. Modified versions of previously established L1 ret-
rotransposition assays80–83 were performed and are described below56. In the Neo/
Blast assays, 2 × 105 HeLa JVM cells were plated in 6-well tissue culture plates.
Within 24 h, cells were co-transfected with 0.5-1 µg of L1 plasmid and 60 nM of let-
7 mimic or 40 nM of let-7 inhibitor and their respective controls, scr, and c-, using
Dharmafect DUO (Dharmacon) following manufacturer’s instructions. For Neo
assays, selection with 400 µg/mL of G418 (Life) was started 48 h post-transfection.
For Blast assays, selection with 10 µg/mL of blasticidin (Millipore) was started
5 days post-transfection. In both cases, medium was changed every 2 days. Between
12 and 14 days after transfection, cells were washed with 1× PBS (Gibco), fixed (2%
formaldehyde, 0.2% glutaraldehyde in 1× PBS), and stained with 0.5% crystal
violet. Colonies were manually counted. The number of antibiotic-resistant colo-
nies was used to quantify retrotransposition levels in cultured cells. Clonability
assay was performed with 0.5 µg pU6i Neo and 1 × 105 HeLa cells84.
Luciferase retrotransposition assays were performed as follows. 1 × 105
HEK293T/SK-MES-1 or 8 × 104 A549 cells were plated in 24-well tissue culture
plates. Next day, 200 ng of pYX014, pYX015, or pYX017 were co-transfected with
60 nM of let-7 mimic or 40 nM of let-7 inhibitor (and their respective controls, scr,
and c- respectively) using Lipofectamine 2000 (Life). Luciferase activity was
measured 96 h post-transfection using Dual-Luciferase Reporter Assay System
(Promega), in a GloMax Luminometer (Promega). Untransfected cells were used to
correct for luciferase background.
EGFP-based retrotransposition assays were performed as follows. 4 × 105
HEK293T cells were plated in 6-well tissue culture plates. Next day, cells were co-
transfected with 1 µg 99-UB-LRE3 and 40 nM of let-7 inhibitor or its control, c-,
using Lipofectamine 2000 (Life). Retrotransposition (EGFP+ cells) was quantified
8 days post-transfection in a FACS Canto cytometer (BD).
miRNAs mimics and inhibitors. Let-7a/b mimic (C-300473-05 and C-300476-05),
miR-34 mimic (C-300551-07), let-7a hairpin inhibitor (IH-300474-07), and their
respective controls scr and c- (CN-002000-01-05 and IN-002005-01-05), were
purchased from Dharmacon. They were resuspended in 1× siRNA Buffer (Thermo)
to a working concentration of 20 µM and kept at −80 °C.
RNA immunoprecipitation (RIP). 2 × 106 PA-1 cells were transfected in 10 cm
tissue culture plates with 4 µg of FLAG-AGO2 and 25 nM of scr/mimic let-7 using
lipofectamine 2000 (Life). Transfection with pBSKS (an empty plasmid) was used
as a negative control for the IP. 48 h post-transfection, cells were washed with ice-
cold 1× PBS, scraped, and transferred to a 1.5 ml tube. After centrifugation at 200g
for 2 min, cells were resuspended in 200 µl of cold resuspension buffer (20 mM Tris
(pH= 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA) containing 1U/µL RNAsin
Plus (Promega) and lysed adding 800 µl of cold lysis buffer (1% Triton X-100, 20
mM Tris (pH= 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
phenylmethyl-sulfonyl fluoride (PMSF, Sigma), 1X cOmplete EDTA-free Protease
Inhibitor cocktail (Roche) and incubating for 10–30 min on ice. After centrifuga-
tion (10,000g for 10 min at 4 °C), 10 µL of RQ1 Dnase (Promega) was added to the
supernatant. Immunoprecipitation of FLAG-AGO2 was performed with Dyna-
beads Protein G (Life) and anti-FLAG M2 mouse (Sigma, F3165) for 3 h at 4 °C
with rotation. After five washes with lysis buffer, 10% of sample-beads were used
for protein extraction and western blot by adding LDS sample buffer and DTT and
heating the samples at 70 °C for 20 min. The 90% of sample beads were incubated
with RQ1 DNAse for 30 min for later RNA extraction with Trizol LS (Ambion).
siCHECK luciferase assays. In 24-well plates, 1 × 105 HEK293T cells were seeded
per well. Within 24 h after seeding, cells were co-transfected with 10 ng of each
siCHECK plasmid and 50–80 nM scr/let-7 mimic using Lipofectamine 2000 (Life).
24 h post-transfection, Firefly and Renilla luciferase measurements were performed
in a GloMax Luminometer (Promega) using Dual-Luciferase® Reporter Assay
System (Promega), following manufacturer’s instructions.
Site-directed mutagenesis. Binding site mutant “bs2rhmut” was generated using
an established protocol. Briefly, two sequential PCRs were performed, using an
active L1.3 as a template. First, two PCRs were performed using the following
primers under standard conditions: Let7-ORF2PCRafw/Let7-ORF2PCRa_PG2rv
and Let7-ORF2PCRarv/Let7-ORF2PCRa_PG2fw. The products of both reactions
were purified, mixed in equal amounts, and used as a template for a second PCR
using primers Let7-ORF2PCRafw/ Let7-ORF2PCRarv. Conditions for this PCR
were: 95 °C 5min, 10 cycles with (95 °C 15 s, 50 °C 30 s, 72 °C 60 s), 25 cycles with
(95 °C 15 s, 55 °C 30 s, 72 °C 60 s), 72 °C 10 min. The resulting product contained
the mutated sequence in ORF2. This product was purified and cloned into a
plasmid containing an active L1 (pJCC5/L1.3) using EcoNI and BsaBI sites, gen-
erating pJCC5/bs2mutL1.3. This mutant L1 was then cloned into pJM101 using
NotI and BstZ17I sites, generating pJM101/bs2mutL1.3.
Binding site mutant 8-mer (pSA500 ORF2-8mer) was generated using the same
protocol described above. For the first two PCRs, primers used were Let7-Bcl1-
ORF2bs-PCRaFw/Let7-ORF2PCRa_8mer and Let7-ORF2PCRb_8mer/pCEP4_Rv.
The products of both reactions were purified, mixed in equal amounts, and used as
a template for a second PCR using primers Let7-Bcl1-ORF2bs-PCRaFw/
pCEP4_Rv. The product was purified and cloned into pSA500 using BclI and
BstZ17I sites.
Restriction enzymes were purchased from New England Biolabs (NEB).
Generation of 3′UTR variants of pSA500. Sequences were ordered as oligos
flanked by a BstZ17I site (See Supplementary Table 10). First, 1 µL of each Fw and
Rv were annealed and phosphorylated with T4 Polynucleotide Kinase (PNK, NEB)
using the following program: 30 min at 37 °C, 5 min at 95 °C, and then down to
25 °C at −5 °C/min. They were cloned in 3′UTR of pSA500 using a BstZ17I site,
generating pSA500-3′UTR-scrb/bs2rh/8mer. Constructs were checked by digestion
and Sanger sequencing.
Western blot. Cells were washed with 1× PBS, trypsinised and pelleted at 200g for
4 min. To extract proteins, cell pellets were resuspended in 50–100 µL of RIPA
buffer (Sigma) supplemented with 1× Complete EDTA-free Protease Inhibitor
cocktail (Roche), PMSF (Sigma), 0.25% β-mercaptoethanol (Sigma) and incubated
for 10 min on ice. Extracts were then centrifuged (18,000g at 4 °C for 10 min) and
debris-free supernatants were transferred to new tubes. Protein concentration was
determined using the Micro BCA Protein Assay Kit (Thermo) following the
manufacturer’s instructions.
To control the transfection efficiency in pSA500 western blots, three fractions of
the cells were pelleted in different tubes after trypsinization, and DNA, RNA, and
protein extractions were performed simultaneously.
Proteins were resolved on an SDS-PAGE gel and transferred to a nitrocellulose
membrane (BioRad). In L1-ORF2p western blots, proteins were resolved in a
4–15% Mini-PROTEAN TGX Precast Gels (BioRad), and transferred to a PVDF
membrane using Trans-Blot Turbo Mini PVDF Transfer Packs (BioRad) and the
Trans-Blot Turbo Transfer System (BioRad).
For western in Supplementary Fig. 5m, HEK-293T cells were transfected with
plasmid constructs indicated and then selected for 1 week by hygromycin (100 μg/
mL). Transfected cells were lysed and L1 RNP were enriched on sucrose cushion by
ultracentrifugation. 3 μg of L1 RNP prep were loaded per lane and resolved in
4–10% gradient SDS-PAGE gels.
For blotting we used the following antibodies: a polyclonal rabbit anti-L1-
ORF1p (1:1000, provided by Dr. Oliver Weichenrieder, Max-Planck, Germany), a
polyclonal rabbit anti-L1ORF1p (1:1000, SE-6798), anti HMGA2 (1:1000, Abcam),
anti DICER (1:1000, Cell Signalling), anti-tubulin (1:1000, Santa Cruz), anti-actin
(1:10000, Sigma, A2228), anti-GFP (1: 2000, 3H9 clone, Chromotek). For
chemiluminescent detection, we used anti-rabbit HRP (1:1000, Cell Signaling) or
anti-mouse HRP (1:1000, Cell Signaling), and Clarity ECL Western Blotting
Substrate (BioRad) or SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo). Images were acquired with an ImageQuant LAS4000 and quantified
using ImageJ software. For Odyssey analysis, anti-rabbit and anti-mouse
fluorescent antibodies (LI-COR) were used at 1:10000 dilution, and detection and
quantification were performed in Odyssey (LI-COR).
qPCR and RT-qPCR. To control plasmid transfection in L1-ORF2p western blots,
transfected cells were lysed in a buffer containing 10 mM Tris pH=8.2, 10 mM
EDTA, 200 mM NaCl, 0.5%SDS and 200 µg/ml proteinase K, and incubating for 3
h at 56 °C with agitation. Afterwards, DNA was purified with phenol:chloroform:
isoamyl alcohol (25:24:1, Thermo) following standard procedures. 50 ng of each
DNA sample were used per qPCR reaction (GoTaq qPCR Mix, Promega), and an
untransfected control was used to discard plasmid contamination. qPCR method is
as follows: 5 min at 95°, and 40 cycles of 15 s at 95° followed by 60 s at 60 °C.
Plasmid levels were quantified using CMV and EBNA-1 primers, and normal-
ization was performed using genomic GAPDH primers.
RNA was extracted from cells using Trizol (Invitrogen), following the
manufacturer’s instructions. 1 µg of RNA was subsequently treated with RQ1
DNAse and purified by a phenol/chlorophorm extraction. cDNA was synthesized
using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems), and
used for qPCR (GoTaq qPCR Mix, Promega) using standard protocols. Two
controls were used to verify the absence of contaminating gDNA: no-RT and no-
template. Endogenous L1 mRNA was quantified using N51 primers85. Transfected
L1 mRNA was quantified using NEOjunct2 primers designed to exclusively amplify
the spliced NEO cDNA86 (in Supplementary Fig. 5a, b) or SV40 primers when the
NEO cassette was absent (Fig. 5c and Supplementary Fig. 5h, k). GAPDH was used
to normalize in Fig. 5c because an additional qPCR was used to quantify plasmid
levels and discard differences in transfection efficiency. Elsewhere, EBNA mRNA,
expressed from the backbone of the plasmids, was used to normalize.
For mature miRNAs quantification, a RT-qPCR was used. 1 µg of total RNA
isolated with Trizol was polyadenylated and then cDNA was synthesized, using
qScript miRNA cDNA synthesis Kit (QuantaBio). Quantitative PCR was
performed using a universal primer against poly(A) and a miRNA-specific primer
that allows the specific detection of polyadenylated mature miRNA and not its
precursors (QuantaBio). qPCR was performed with primers Let-7a, Let-7b, and
miR-34a.
Flow cytometry. In 6-well plates, 2 × 105 HeLa cells were seeded per well. Next
day, cells were transfected with 1 µg of pVan583 and 40 nM c-/let7inh using
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lipofectamine 2000 (Life). Seventy-two hours post-transfection, cells were washed
with 1× PBS (Life), detached with TrypLE Express (Gibco) for 5–10 min at 37 °C,
pelleted 4 min at 200g, resuspended in 1× PBS with 5% FBS and 5mM EDTA, and
passed through a 70 µM filter. After incubation with 10ug/mL 7AAD (Sigma) for
10 min, fluorescence was quantified in a FACSAria (BD) cytometer. For each
replicate, 105 cells were passed through the cytomerer. Only live and transfected
cells (7AAD– and GFP+, between 3600 and 9300 cells) were used for %mCherry
analysis, which was performed using FlowJo software (LLC) version 10. Controls
were used to set the threshold for each fluorescent channel of detection:
untransfected cells, and cells expressing either GFP only or mCherry only.
Confocal microscopy. 2 × 105 U2OS per well were seeded in 6-well tissue culture
plates. Next day, cells were transfected with 1 µg of DNA and 60 nM scr/mimic
using lipofectamine 2000 (Life), following standard protocols. Twenty-four hours
post-transfection, cells were detached and re-seeded in 24-well plates where a UV-
sterilized glass slide had previously been placed. Forty-eight hours post-transfec-
tion, cells were washed in 1× PBS, fixed in paraformaldehyde (4% in 1× PBS) for
30 minutes at room temperature, and slides were mounted with Slow-Fade Gold
Antifade reagent with DAPI (Life). Slides were imaged using a Zeiss LSM-710
confocal microscope (Leica).
Hybridization between let-7 and L1 prediction. The potential structure formed
by let-7 and WT L1 or its binding site mutant was analyzed by RNAHybrid69.
Briefly, the region of L1Hs identified as “bs2” with RNA22 was paired to the
mature sequence of let-7, using default parameters.
Plasmids. pYX014, pYX015 and pYX01783, JM101/L1.370, JM105/L1.34, JJ101/
L1.387 and TAM102/L1.380, 99-UB-LRE388, Tgf21-Neo89, Zfl2-1-Neo, and Zfl2-2-
Neo90 have been previously described. JJ101/L1.3Δ3’UTR is a derivative of JJ101/
L1.3 but the L1 lacks the 3′UTR45. JM101/L1.3bs2mut was generated by cloning a
bs2mut L1 into JM101/L1.3 (cloning strategy described in the “Site-directed
mutagenesis” section of the methods). FLAG-Ago1 and FLAG-Ago2 were a gift
from Edward Chan (Addgene plasmid #21533 and #21538)91. pSA500 is as
pAD50063 where the TAP epitope was replaced by 3 consecutive copies of the
FLAG epitope tag obtained from PJCC5 ORF1T7 ORF3XFLAG using BclI and
BstZ17I restriction enzyme sites. pVan583 is a derivative of JM101/L1.3 where
EGFP and mCherry were cloned in frame with the last amino acid of L1-ORF1 and
L1-ORF2, respectively. All psiCHECK2 constructs were generated by cloning
sequences synthesized and cloned in pUC57 (Genescript) into psiCHECK2 using
XhoI and NotI restriction enzyme sites (Promega).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data sets used in Fig. 1 and Supplementary Fig. 1 are detailed in Supplementary Table 1.
All data are available from the GDC legacy archive (https://portal.gdc.cancer.gov/legacy-
archive). Though most data files can be accessed without requiring access approval, WGS
files need a special request due to their potential identification information. Researchers
interested in accessing restricted data can obtain authorization following the instructions
in https://gdc.cancer.gov/access-data/obtaining-access-controlled-data. Uncropped
versions of the western blots are provided in Supplementary Fig. 6. The data supporting
the findings of this study are available from the corresponding authors upon reasonable
request. Source data are provided with this paper.
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